<DOC>
	<DOC>NCT00642850</DOC>
	<brief_summary>This single arm study will assess the efficacy, safety and tolerability of once-monthly administration of intravenous Mircera for the maintenance of hemoglobin levels in dialysis participants with chronic renal anemia. Participants will receive monthly intravenous injections of Mircera, at a starting dose of 120, 200 or 360 micrograms, according to the dose of epoetin administered in the week preceding first study drug administration. The anticipated time on study treatment is 3-12 months, and the target sample size is 100-500 individuals.</brief_summary>
	<brief_title>STABIL Study: National Study With Mircera for Maintenance of Hemoglobin Level in Dialysis Patients</brief_title>
	<detailed_description />
	<mesh_term>Anemia</mesh_term>
	<criteria>Chronic renal anemia; Continuous stable intravenous maintenance epoetin therapy during previous month; Regular longterm hemodialysis therapy with the same mode of dialysis for previous 3 months. Transfusion of red blood cells during previous 2 months; Poorly controlled hypertension, that is, sitting blood pressure exceeding 170/100 millimeter of mercury (mmHg) despite medication; Significant acute or chronic bleeding.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>